

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

(1) AUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023; AND (2) RESUMPTION OF TRADING

Reference is made to the announcements of the Company dated March 28, 2024 (the “**Announcements**”) on (i) the 2023 Unaudited Annual Results; and (ii) delay in publication of the 2023 Annual Results. Unless the context requires otherwise, capitalized terms in this announcement shall have the same meaning as they are used in the Announcements.

2023 ANNUAL RESULTS

The Board is pleased to announce that the audit of the 2023 Annual Results have been completed in accordance with International Standards on Auditing issued by the International Auditing and Assurance Standards Board. The Company’s auditor, PricewaterhouseCoopers, have expressed unqualified opinion in the independent auditor’s report.

The 2023 Annual Results (including the consolidated balance sheet, consolidated statement of comprehensive loss and the related notes thereto) remain the same as those disclosed in the 2023 Unaudited Annual Results.

The 2023 Unaudited Annual Results contained in the Announcements is hereby incorporated to this announcement by reference.

Review of Financial Information

Audit Committee

The Audit Committee has held relevant discussions with the Company's management, and reviewed the 2023 Annual Results. The Audit Committee considered that the 2023 Annual Results are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

Scope of Work of the Company's Auditors

The figures in respect to the Group's consolidated statement of comprehensive loss, consolidated balance sheet and the related notes thereto for the year ended December 31, 2023 have been agreed by the Company's auditors, PricewaterhouseCoopers, to the amounts set out in the Group's audited consolidated financial statements for the year.

The work performed by PricewaterhouseCoopers in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently, no assurance has been expressed by PricewaterhouseCoopers on this announcement.

INSIDE INFORMATION

Save as disclosed in this announcement, the Group does not have any undisclosed inside information.

RESUMPTION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules and at the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 2, 2024. In light of the publication of this announcement, an application has been made by the Company to the Stock Exchange for the resumption of trading in the Shares with effect from 9:00 a.m. on June 17, 2024.

PUBLICATION OF THE 2023 ANNUAL RESULTS AND ANNUAL REPORT

This announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and the Company's website (www.peijiamedical.com). The annual report of the Company for the Reporting Period containing all the information required by the Listing Rules will be dispatched to Shareholders and published on the above websites in due course.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, June 16, 2024

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei as independent non-executive Directors.